Gabapentin Capsule
Product Images NDC 71205-661

7 FDA label images from Proficient Rx Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-661). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gaba-fig-1-jpg.jpg (Gaba Fig 1 Jpg)

Gaba-fig-1-jpg.jpg (Gaba Fig 1 Jpg)
A line graph showing mean pain scores over 8 weeks comparing Gabapentin 3600 mg/day and placebo. The x-axis represents weeks, with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain score from 0 to 10. Gabapentin's pain scores decline steadily, while placebo scores remain relatively stable.*
FDA Label Image

Gaba-fig-2-jpg.jpg (Gaba Fig 2 Jpg)

Gaba-fig-2-jpg.jpg (Gaba Fig 2 Jpg)
Line graph showing mean pain score over weeks comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The X-axis represents weeks, dividing a 3-week dose titration period and a 4-week fixed dose period, while the Y-axis shows mean pain scores from 0 to 10. Scores decrease over time for both gabapentin doses compared to placebo.*
FDA Label Image

Gaba-fig-3-jpg.jpg (Gaba Fig 3 Jpg)

Gaba-fig-3-jpg.jpg (Gaba Fig 3 Jpg)
A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing two studies. Study 1 compares placebo (PBO) at 12% responder rate to Gabapentin (GBP) 3600 mg with 29%. Study 2 compares placebo at 14% to GBP 1800 mg at 32% and GBP 2400 mg at 34%. Statistical significance is noted with p-values of less than 0.01 and 0.001.*
FDA Label Image

Gaba-fig-4-jpg.jpg (Gaba Fig 4 Jpg)

Gaba-fig-4-jpg.jpg (Gaba Fig 4 Jpg)
A scatter plot comparing the percentage difference versus daily dose (mg) for three separate studies labeled a, b, and c. The x-axis represents the daily dose in mg, ranging from 600 to 1800 mg, while the y-axis shows the percentage difference, ranging from 2% to 22%. Study a is represented by black squares, Study b by gray squares, and Study c by white squares, with each study having data points at varying daily doses.*
FDA Label Image

Gaba-structure.jpg (Gaba Structure)

Gaba-structure.jpg (Gaba Structure)
Chemical structure of Gabapentin showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxymethyl group (CH2CO2H).*
FDA Label Image

71205-661-15 (Gabapentin 100mg 500 Jpg)

71205-661-15 (Gabapentin 100mg 500 Jpg)
Packaging label for Gabapentin 100 mg capsules by Proficient Rx LP, lot number 00000, NDC 71205-661-15. The label states each capsule contains 100 mg gabapentin in a hard gelatin capsule, white opaque body and cap, imprinted with G 56 black ink. Manufactured by Granules India Limited, Hyderabad, India, and stored at 20°-25°C (68°-77°F). The package contains 15 capsules and is labeled RX only.*
FDA Label Image

Gabapentin-formula-jpg.jpg (Gabapentin Formula Jpg)

Gabapentin-formula-jpg.jpg (Gabapentin Formula Jpg)
A formula calculating creatinine clearance (CLCr) based on patient age, weight, serum creatinine, and a factor for female patients. The formula includes adjustments for age (years), weight (kg), and serum creatinine (mg/dL) to estimate kidney function.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.